Medical Advocates
Abacavir (Ziagen)
 
Journal Citations: Adverse Events

General Reports
Agranulocytosis
 Cardiovascular Disorders
Fanconi's  Syndrome
 Hypersensitivity
 Metabolic Changes: General
 Renal Disorders
 Bone Disorders
 Hepatic Disorders
 
Abacavir Journal Citations Main New/Newsworthy    Home Page    
Last Updated:  February 10, 2018
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 Notice: ABC/3TC/ZDV data are indexed on the Trizavir Web
General /Miscellaneous Reports
       
 
Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis.
 Jesson J, Dahourou DL, Renaud F, et al
Lancet HIV. 2016 Feb;3(2):e64-75
 Abstract

FULL-TEXT ARTICLE
 Alopecia areata associated with abacavir therapy.
Kim HS, Shin HS.
Infect Chemother. 2014 Jun;46(2):103-5.
 Paper

Impact of the Data Collection on Adverse Events of Anti-HIV Drugs Cohort Study on Abacavir Prescription Among Treatment-Naive, HIV-Infected Patients in Canada.
 Antoniou T, Gillis J, Loutfy MR, et al
J Int Assoc Provid AIDS Care. 2013 Jul 25
 Abstract

Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.
Norcross MA, Luo S, Lu L, et al
AIDS. 2012 May 19
Abstract

Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.
Berka N, Gill JM, Liacini A, O'Bryan T, Khan FM.
Hum Immunol. 2011 Dec 8
 Abstract
Agranulocytosis
       
  FULL-TEXT ARTICLE
 Agranulocytosis induced by abacavir.
 Tikhomirov V, Namek J, Hindes R, et al
AIDS. 13(11):1420, July 30, 1999.
 Paper
Cardiovascular Disorders
       
 
Recent abacavir use increases risk for Types 1 and 2 myocardial infarctions among adults with HIV.
Elion RA, Althoff KN, Zhang J,  et al
J Acquir Immune Defic Syndr. 2018 Feb 6.
Abstract

Abacavir induces arterial thrombosis in a murine model.
Collado-Diaz V, Andujar I, Sanchez-Lopez A, et al
J Infect Dis. 2018 Jan 16.
 Abstract

FULL-TEXT ARTICLE
 Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.
Dorjee K, Baxi SM, Reingold AL, Hubbard A.
 BMC Infect Dis. 2017 Oct 27;17(1):708.  
Paper

Abacavir use and risk of recurrent myocardial infarction: the D: A: D Study.
Sabin CA, Ryom L, d'Arminio Monforte A, et al
 AIDS. 2017 Oct 12.
Abstract

Cardiovascular toxicity of Abacavir: a clinical controversy in need of a pharmacological explanation.
Alvarez A, Orden S, Andújar I, et al
AIDS. 2017 May 23.
Abstract

Abacavir and cardiovascular disease: A critical look at the data.
Llibre JM, Hill A. 
Antiviral Res. 2016 May 31
 Abstract

FULL-TEXT ARTICLE
 Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.
Sabin CA, Reiss P, Ryom L, et al
BMC Med. 2016 Mar 31;14(1):61.
 Paper

Use of abacavir and risk of cardiovascular disease among HIV-infected individuals.
 Marcus JL, Neugebauer RS, Leyden WA, et al
J Acquir Immune Defic Syndr. 2015 Nov w
Abstract
The effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study.
 Young J, Xiao Y, Moodie EE, et al 
J Acquir Immune Defic Syndr. 2015 Apr 28.
 Abstract

Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study
Wohl DA, Arnoczy G, Fichtenbaum CJ,  et al
 Antivir Ther. 2013 Aug 28.
Abstract

No Association of Abacavir Use with Myocardial Infarction: Findings of an FDA Meta-analysis.
Ding X, Andraca-Carrera E, Cooper C,  et al
J Acquir Immune Defic Syndr. 2012 Aug 28
 Abstract

Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
Patel P, Bush T, Overton T, Baker J,  et al
 Antivir Ther. 2011 Dec 16
 Abstract

FULL-TEXT PDF ARTICLE
 Evaluation of Cardiovascular biomarkers In HIV-infected Patients Switching to Abacavir or
Tenofovir Based Therapy
 Rasmussen TA, Tolstrup M, Melchjorsen J,  et al
BMC Infectious Diseases 2011, 11:267
 Paper

Increased Platelet Reactivity in HIV-1-Infected Patients Receiving Abacavir-Containing Antiretroviral
Therapy.
 Satchell CS, O'Halloran JA, Cotter AG,  et al
J Infect Dis. 2011 Oct;204(8):1202-10.
 Abstract

Impact of Tenofovir Versus Abacavir on HIV-Related Endothelial Dysfyunction.
Francisci D, Falcinelli E, Belfiori B,  et al 
AIDS Patient Care STDS. 2011 Aug 18
 Abstract

ABACAVIR use and cardiovascular disease events: a meta-analysis of published and unpublished data.
 Cruciani M, Zanichelli V, Serpelloni G,  et al
AIDS. 2011 Jun 29.
Abstract

Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era.
 Bedimo RJ, Westfall AO, Drechsler H, et al
 Clin Infect Dis. 2011 Jul;53(1):84-91.
 Abstract
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
 Choi AI, Vittinghoff E, Deeks SG,  et al
AIDS. 2011 Apr 21.
 Abstract

FULL-TEXT PDF ARTICLE
 Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir.
 Padilla S, Masia M, Garcia N, et al
BMC Infect Dis. 2011 Feb 4;11(1):40
 Paper

Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.
Schafer JJ, Short WR, Squires KE.
Pharmacotherapy. 2010 Oct;30(10):1072-83.
 Abstract

Abacavir and Cardiovascular Risk: Reviewing the Evidence.
 Costagliola D, Lang S, Mary-Krause M, Boccara F.
Curr HIV/AIDS Rep. 2010 Jun 3
 Abstract

Implementing the number needed to harm in clinical practice:risk of myocardial infarction in HIV-1-infected patients treated with abacavir.
 Kowalska JD, Kirk O, Mocroft A,  et al
HIV Med. 2010 Mar;11(3):200-8.
 Abstract

Abacavir and cardiovascular risk.
 Behrens GM, Reiss P.  
Curr Opin Infect Dis. 2009 Dec 4
 Abstract

Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy.
 Kristoffersen US, Kofoed K, Kronborg G, et al
HIV Med. 2009 Nov;10(10):627-33
 Abstract

Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.
Kowalska J, Kirk O, Mocroft A, et al
HIV Med. 2009 Oct 27.
 Abstract

Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.
 Obel N, Farkas D, Kronborg G, Larsen C, et al 
HIV Med. 2009 Aug 13.
 Abstract

Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients.
Hsue PY, Hunt PW, Wu Y, et al 
AIDS. 2009 Jun 17
 Abstract

Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects.
 Brothers CH, Hernandez JE, Cutrell AG, et al 
J Acquir Immune Defic Syndr. 2009 Mar 11
 Abstract
Fanconi's  Syndrome
       
  Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome.
 Ahmad M. 
J Postgrad Med. 2006 Oct-Dec;52(4):296-7.
 Abstract
Hypersensitivity
 
 
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.
Roen A, Laut K, Pelchen-Matthews A, et al
IV Med. 2017 Dec 22.

A severe hypersensitivity reaction to abacavir following re-challenge.
Todd S, Emerson CR.
Int J STD AIDS. 2016 Aug 16.
Abstract

Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?
 Kapoor R, Martinez-Vega R, Dong D,  et al
Pharmacogenet Genomics. 2014 Nov 28
 Abstract

The frequency of HLA-B∗57:01 and the risk of abacavir hypersensitivity reactions in the majority population of Costa Rica.
 Arrieta-Bolaños E, Alejandro Madrigal J, Marsh SG, et al
Hum Immunol. 2014 Oct 3.
 Abstract

Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
Guo Y, Shi L, Hong H, et al
Sci China Life Sci. 2013 Feb;56(2):119-24.
 Abstract

FULL-TEXT LETTER
In Mexican Mestizos the HCP5 rs2395029 SNP may be a genetic marker for screening abacavir hypersensitivity.
Sanchez-Giron F, Carnevale A.
Pharmacogenomics. 2012 Feb;13(3):251-2
 Letter

HLA-B*5701 and abacavir hypersensitivity reaction.
 Servonnet A, Leclercq E, Delacour H, Ceppa F.
 Pathol Biol (Paris). 2009 Feb 23
 Abstract
 
Current trends in screening across ethnicities for hypersensitivity to abacavir.
 Rodriguez-Nóvoa S, Soriano V. 
Pharmacogenomics. 2008 Oct;9(10):1531-41.
 Abstract
 
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
Young B, Squires K, Patel P, et al
AIDS. 2008 Aug 20;22(13):1673-5
 Abstract
 
Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.
 Hughes AR, Spreen WR, Mosteller M, et al
Pharmacogenomics J. 2008 Mar 11
 Abstract
 
Abacavir Hypersensitivity Reaction: an Update (March) (CE).
 Hughes CA, Foisy MM, Dewhurst N, et al 
Ann Pharmacother. 2008 Feb 26
Abstract
 
Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects with Prior Nucleoside Analog Experience.
 Demeter LM, Degruttola V, Lustgarten S, et al
 HIV Clin Trials. 2008 Jan-Feb;9(1):11-25
 Abstract
 
Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
Sun HY, Hung CC, Lin PH, et al
 J  Antimicrob Chemother. 2007 Jul 12;
 Abstract
 
Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.
Martin AM, Almeida CA, Cameron P, et al 
AIDS. 2007 Jun;21(10):1233-1244.
 Abstract

A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
 Chui CK, Brumme ZL, Brumme CJ, et al 
Clin Infect Dis. 2007 Jun 1;44(11):1503-8.
 Abstract

Prospective Screening for Human Leukocyte Antigen-B*5701 Avoids Abacavir Hypersensitivity Reaction in the Ethnically Mixed French HIV Population.
 Zucman D, de Truchis P, Majerholc C, et al 
J Acquir Immune Defic Syndr. 2007 Mar 8;
 Abstract

Identification of abacavir hypersensitivity reaction in health care claims data.
Nordstrom BL, Norman HS, Dube TJ, et al  
Pharmacoepidemiol Drug Saf. 2007 Jan 24
 Abstract
 
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
Gervasoni C, Vigano O, Grinelli E, et al
AIDS Patient Care STDS. 2007 Jan;21(1):1-3.
 Abstract
 
Abacavir hypersensitivity reaction in primary HIV infection.
 Stekler J, Maenza J, Stevens C
AIDS. 2006 Jun 12;20(9):1269-74.
 Abstract
 
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
Rauch A, Nolan D, Martin A, et al
 Clin Infect Dis. 2006 Jul 1;43(1):99-102
 Abstract
 
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.
Martin A, Nolan D, Almeida CA, Rauch A, Mallal S.
Pharmacogenomics. 2006 Jan;7(1):15-23.
Abstract
 
Clinical and immunogenetic correlates of abacavir hypersensitivity.
 Phillips EJ, Wong GA, Kaul R, et al  
AIDS. 2005 Jun 10;19(9):979-981.
 Abstract
 
[Abacavir Hypersensitivity Syndrome
 Chirouze C, Hustache-Mathieu L, et al   
 Pathol Biol (Paris). 2004 Nov;52(9):529-33.
 Abstract
 
Unusual clinical presentation of hypersensitivity reaction to abacavir.
Aquilina C, Mularczyk M, Lucas F, Viraben R,
AIDS. 17(16):2403-2404, November 7, 2003.
Letter
Epidemiological risk factors for hypersensitivity reactions to abacavir.
Easterbrook PJ, Waters A, Murad S, et al  
HIV Med. 2003 Oct;4(4):321-324.
 Abstract
 
Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a
case report.
 Lanzafame M, Trevenzoli M, Lattuada E, et al.
 Infez Med 2003 Mar;11(1):40-1
 Abstract
Abacavir hypersensitivity reaction.
Hewitt RG.
Clin Infect Dis 2002 Apr 15;34(8):1137-42
 Abstract

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1reverse-transcriptase inhibitor abacavir.
 Mallal S, Nolan D, Witt C, et al.
 Lancet 2002 Mar 2;359(9308):727-32
 Abstract
 
Understanding drug hypersensitivity: what to look for when prescribing abacavir.
Hetherington S.
AIDS Read 2001 Dec;11(12):620-2
 Abstract

A near-fatal hypersensitivity reaction to abacavir: case report and literature review.
Shapiro M, Ward KM, Stern JJ.
AIDS Read 2001 Apr;11(4):222-6
 Abstract

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
 Hetherington S, McGuirk S, Powell G, et al.
Clin Ther 2001 Oct;23(10):1603-14
 Abstract
 
FULL-TEXT ARTICLE
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
Wit F,Wood R, Horban A, et al
AIDS. 15(18):2423-2429, Dec 7, 2001.
 Paper
Metabolic Changes: General
       
 
From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.
Curran A, Ribera E.
 Expert Opin Drug Saf. 2011 Jan 17.
 Abstract

Body Composition and Metabolic Changes in Antiretroviral-Naive Patients Randomized to Didanosine and Stavudine vs. Abacavir and Lamivudine.
 Shlay JC, Visnegarwala F, Bartsch G,et al
 J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):147-155
 Abstract

Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.
 Venhoff N, Setzer B, Melkaoui K, Walker UA.
 Antivir Ther. 2007;12(7):1075-85.
 Abstract
Renal Disorders
       
  FULL-TEXT ARTICLE
 Abacavir-induced liver toxicity.
Pezzani MD, Resnati C, Di Cristo V, Riva A, Gervasoni C.
Braz J Infect Dis. 2016 Apr 4
 Paper

FULL-TEXT ARTICLE
 Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial.
 Rasmussen TA, Jensen D, Tolstrup M, et al
PLoS One. 2012;7(3):e32445.
Paper

FULL-TEXT ARTICLE
 Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Naïve Patients with HIV Infection.
 Nishijima T, Gatanaga H, Komatsu H, et al
PLoS One. 2012;7(1):e29977.
 Paper
Bone Disorders
       
  Prevalence and Risk Factors of Low Bone Mineral Density in Korean HIV-Infected Patients: Impact of Abacavir and Zidovudine.
Kim HS, Chin BS, Shin HS.J
Korean Med Sci. 2013 Jun;28(6):827-32.
Abstract

FULL-TEXT ARTICLE
 Comparison of Bone and Renal Effects In HIV-infected Adults Switching to Abacavir or Tenofovir Based Therapy in a Randomized Trial.
 Rasmussen TA, Jensen D, Tolstrup M, et al
PLoS One. 2012;7(3):e32445.
Paper
Hepatic Disorders
       
  Abacavir-induced liver toxicity.
Pezzani MD, Resnati C, Di Cristo V, et al
Braz J Infect Dis. 2016
 Abstract

The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction.
Blas-García A, Martí-Rodrigo A, Víctor VM, et al
J Antimicrob Chemother. 2016 Jan 7
 Abstract

 
Abacavir Journal Citations Main New/Newsworthy    Home Page    

Abacavir Journal Papers,  Abstracts, and Commentaries
 Adverse Events